A Long-term Open-label Study of the Safety and Tolerability of Cariprazine in Patients With Bipolar I Disorder.

Trial Profile

A Long-term Open-label Study of the Safety and Tolerability of Cariprazine in Patients With Bipolar I Disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2013

At a glance

  • Drugs Cariprazine (Primary)
  • Indications Bipolar I disorders
  • Focus Adverse reactions; Pharmacogenomic; Registrational
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 09 Oct 2013 Results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
    • 19 May 2013 Results will be presented at the American Psychiatric Association (APA) annual meeting, according to a Forest Laboratories media release.
    • 10 Apr 2012 Actual patient number is 203 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top